CD8A and neoplasm: Moreover, immunogenic cell death of virally infected tumor cells releases both tumor-associated antigens and neoantigens that can be acquired and presented by antigen-presenting cells, leading to the induction of antitumor CD8+ T cell responses (an approach often described as “in situ vaccination”) [145,146].